- TRADE NAME: Leqvio (Novartis)
- INDICATIONS: Adjunct to diet and statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.
- CLASS: Small interfering RNA (siRNA)
- HALF-LIFE: Approximately 9 hours
- FDA APPROVAL DATE: 12/22/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Discontinue inclisiran when pregnancy is recognized.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
